GlassScriptPhysician profile
Bresha Patton
NPI 1336602382
$4,348.31
in general payments reported to CMS, 2019-2025
31 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.79 · 2022: $210 · 2023: $1,534 · 2024: $1,521 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,975.17 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $553.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $467.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $435.22 | 2023-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $421.17 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $395.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $291.56 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $241.51 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.10 | 2023-2025 | Xifaxan |
| Exact Sciences Corporation | $160.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $134.97 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $128.51 | 2023 | Veozah, Myrbetriq |
| Lundbeck LLC | $123.48 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $118.46 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $111.61 | 2023 | Quviviq |
| Mannkind Corporation | $98.82 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $71.57 | 2022-2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $71.47 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Sanofi-Aventis U.S. LLC | $57.51 | 2022-2024 | |
| Gilead Sciences, INC. | $42.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.74 | 2024 | Spravato |
| Pfizer INC. | $25.33 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.07 | 2024 | Trintellix |
| Medtronic, INC. | $21.72 | 2025 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $21.30 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.27 | 2025 | Jardiance |
| Genzyme Corporation | $20.15 | 2024 | |
| Kci USA, INC. | $19.14 | 2021 | |
| Esperion Therapeutics, INC. | $17.22 | 2023 | Nexletol |
| Amneal Pharmaceuticals LLC | $16.76 | 2023 | Unithroid |
| Merck Sharp & Dohme LLC | $14.87 | 2023 | Belsomra |
| Smith+Nephew, INC. | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bresha Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.